MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  
HCP Resources  Psychiatry  

Patient Resources 
Bipolar  
Diabetes  
Schizophrenia  


Useful Websites

specialistinfo.com
details of 26,000 UK specialists

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

DoctorOnline
information for doctors

The Converter Site
metric and imperial conversion tool.
home > drug information > Lamisil Solution, 1%

Lamisil Solution, 1%


Company: Novartis
Approval Status: Approved March 2001
Treatment for: Dermatologic infections
Areas: Dermatology/Plastic Surgery
Possible similar drugs: Lamisil; Lamisil

| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |


General Information

Other Useful Resources

Lamisil Solution, 1% is a synthetic antifungal compound approved for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur, and tinea pedis (athlete's foot), tinea cruris (jock itch), or tinea corporis (ringworm), due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermaphyton floccosum.

Lamisil Solution, 1% is designed for one week usage and is administered to the infected area once or twice daily, depending on indication.



< back to top

Clinical Results

The effectiveness of Lamisil Solution, 1% was evaluated in separate eight week placebo-controlled trials for tinea (pityriasis) versicolor, tinea pedis, and tinea corporis/cruris, involving a total of 898 subjects. In the majority of pateints, relief of symptoms began within the one week treatment period and continued improvement was recorded over the following seven weeks. (from Lamisil Solution, 1% Prescribing Information)



< back to top

Side Effects

Adverse events associated with the use of terbinafine hydrochloride may include (but are not limited to) the following:


  • site irritation
  • itching
  • skin exfoliation
  • erythematous rash

< back to top

Mechanism of Action

Lamisil Solution, 1% (terbinafine hydrochloride solution) is a synthetic allyamine derivative. Terbinafine hydrochloride is thought to act by inhibiting the epoxidation of squalene, thus blocking the biosysnthesis of ergosterol, an essential component of fungal cell membranes. Depending on the concentration of the drug and the fungal species being tested in vitro, terbinafine hydrochloride may be fungicidal. (from Lamisil Solution, 1% Prescribing Information)



< back to top

Additional Information

For additional information on Lamisil Solution, 1%, please visit Novartis.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.






medilexicon toolbar

download button

Features:

 Medical Dictionary Searches
 ICD9 Searches
 Other Medical Searches
 Search Word Highlighter
 Medical News Articles
 Latest News Headlines

Medical Toolbar

FREE

Download the Medilexicon Medical Search Toolbar on to your internet browser quickly and easily at the touch of a button.

The toolbar will always appear at the top of your internet browser and will allow you to perform many useful features...

>> Click here for more information about the toolbar <<

toolbar



pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<







Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, Mexico Office: + 52 1998 2142733
© 2007 MediLexicon International Ltd. MediLexicon International Ltd